---
title: BCM Breast Cancer Trials
markmap:
  initialExpandLevel: 3
  maxWidth: 200
  colorFreezeLevel: 6
---
- MED ONC
  - Adjuvant
    - HER2
      - NO LINE
        - **FLAMINGO -01**
          
             - [x] Stage I/II with nonpCR OR stage III (pCR or not) to be enorlled <90 days from completion of HP/TDM1
          
          
             - [x] TWO cohorst depending on HLA-A-02
        - **CompassHER2 RD**
          
             - [x] Prior NACT with 6 or more cycles of chemo (at least 9 weeks or THP). If was part of EA1181, must receive 2 more cycles of chemo
          
          
             - [x] ER+ must be ypN+ (1/2/3) with ypT1/2/3. Weak ER+ can be ypN0. Will be randomized to TDM1 vs TDM1 and Tucatinib. May receive ≤ 1 cycle adjuvant T-DM1 prior to registration
        - **CompassHER2 RD**
          
             - [x] Prior NACT with 6 or more cycles of chemo (at least 9 weeks or THP). If was part of EA1181, must receive 2 more cycles of chemo
          
          
             - [x] ER- can be ypT1/2/3 with ypN0/1/2/3. Will be randomized to TDM1 vs TDM1 and Tucatinib. May receive ≤ 1 cycle adjuvant T-DM1 prior to registration
        - **ICE COMPRESS / SWOG S2205**
          
             - [x] NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).
          
          
             - [x] Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's
        - _FLEX_
          
             - [x] T1 to T3, with smallest size 6mm. Any N
    - HR POS
      - NO LINE
        - **CAMBRIA-1**
          
             - [x] Intermediate and High risk to randomize between adjuvant year 2 : 5 to either continue adj. ET SoC vs oral SERD
          
          
             - [x] Intermediate: T3 N0 | T1c/T2 N1 [2-3 LN] | T1c/T2 N0 (Grade III, KI67 >= 20%, LumB/RS26, or prior chemotherapy)
          
          
             - [x] High: Stage III | T1c/T2 N1 [2-3]  (Grade III, KI67 >= 20%, LumB/RS26) | T1c/T2 N1 [1/3] (Grade III, KI67 >= 20%, LumB/RS26)
        - **ICE COMPRESS / SWOG S2205**
          
             - [x] NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).
          
          
             - [x] Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's
        - **OFSET (NRG BR009)**
          
             - [x] ER+ (>1%) HER2- with pT1-3 pN0-1. 
          
          
             - [x] RS N1 <26. RS N0 21-25. RS N0 16-20 WITH T minimum at 30mm (G1), 20mm (G2) or 10mm (G3)
        - _FLEX_
          
             - [x] T1 to T3, with smallest size 6mm. Any N
    - TNBC
      - NO LINE
        - **ICE COMPRESS / SWOG S2205**
          
             - [x] NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).
          
          
             - [x] Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's
        - _Optimize-PCR (A012103)_
          
             - [x] TNBC (<10%)  T1cN1-2 or T2-4N0-2 with ypT0 OR ypTis
          
          
             - [x] Adju RT  and Pembro, followed by registration
        - _ASCENT-05_
          
             - [x] TNBC (<10%) with residual disease 
        - _FLEX_
          
             - [x] T1 to T3, with smallest size 6mm. Any N
  - Metastatic
    - HER2
      - 1
        - STOPHER2 / TBCRC 062
          
             - [x] On 1st Line ABC HER2+ for 3 or more years. If brain disease, has to be stable for 2 or more years
          
          
             - [x] Continue ET therapy. Can be enrolled if ET was changed
        - STOPHER2 / TBCRC 062
          
             - [x] On 1st Line ABC HER2+ for 3 or more years. If brain disease, has to be stable for 2 or more years
    - HR POS
      - 1
        - _EvoPAR-Breast01_
          
             - [x] DenoVo metastatic opr 1ry resistant ER+ (>1%)
          
          
             - [x] BRCA1/2 OR PALB2 (either germline or somatic) 
      - 2
        - **ELAINE-III**
          
             - [x] Progression on 1st Line CDK4/6. ESR1 mutation
        - **OPERA-1**
          
             - [x] Post 1st Line progression while on ET/CDK , adjuvant ET or within 2 years post ET. No prior Chemo in Stage 4. 
          
          
             - [x] Part A three arm for OP 120, OP 90 and SoC. Part B is OP vs SoC [Faslo or AI]
      - 3
        - **OPERA-1**
          
             - [x] Post 2 Lines Line of ET, lasting at least 6 months. No prior Chemo in Stage 4. 
          
          
             - [x] Part A three arm for OP 120, OP 90 and SoC. Part B is OP vs SoC [Faslo or AI]
          
          
             - [x] If 2nd line was Faslo, 3rd line SoC can be AI
    - TNBC
      - 1
        - _TROPION-Breast05_
          
             - [x] PDL1 centrally confirmed TNBC
  - Neoadjuvant
    - HER2
      - NO LINE
        - **RESPONSE**
          
             - [x] 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers
          
          
             - [x] Will receive weekly Taxol HP  with ddAC
        - **ICE COMPRESS / SWOG S2205**
          
             - [x] NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).
          
          
             - [x] Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's
        - _FLEX_
          
             - [x] T1 to T3, with smallest size 6mm. Any N
    - HR POS
      - NO LINE
        - **RESPONSE**
          
             - [x] 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers
          
          
             - [x] High Risk ER+ (Grade III, Age <50, ER < 6/8 OR Ki67 >29%). Will receive weekly Taxol with ddAC
        - **TBCRC042**
          
             - [x] ADH, ALH, LCIS or DCIS requiring excision. T1(mi) is allowed. If undergoing germline testing, results should be available prior to randomization
          
          
             - [x] Ruxo vs Placebo for 15 days +/- 5 days. Surgery within 12 hours of last dose
        - _EVANGELINE_
          
             - [x] Clinical T2 or T3 and N0 or N1 with Grade I and II
          
          
             - [x] ER+ 67% or more, Allred 6-8
        - TBCRC 037
          
             - [x] ILC ER+ POSTmenopausal. Tumor 10mm or more. No HRT in prior 2 years
        - **ICE COMPRESS / SWOG S2205**
          
             - [x] NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).
          
          
             - [x] Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's
        - _NCBRE_
          
             - [x] ILC ER+ PR+ HER2- with ERBB2 mutation.
          
          
             - [x] T1c (Min size 15mm) N0/N1/N2
        - _S2206_
          
             - [x] High 2 on MP
        - _CDK4i PF0060_
          
             - [x] T1 to T3, with smallest size 15mm. Any N. Excludes T4 and N3
        - _FLEX_
          
             - [x] T1 to T3, with smallest size 6mm. Any N
    - TNBC
      - NO LINE
        - **RESPONSE**
          
             - [x] 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers
          
          
             - [x] Will receive weekly Taxol with ddAC (Pembro added if indicated, Carbo added if T3)
        - **TBCRC042**
          
             - [x] ADH, ALH, LCIS or DCIS requiring excision. T1(mi) is allowed. If undergoing germline testing, results should be available prior to randomization
          
          
             - [x] Ruxo vs Placebo for 15 days +/- 5 days. Surgery within 12 hours of last dose
        - **ICE COMPRESS / SWOG S2205**
          
             - [x] NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).
          
          
             - [x] Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's
        - _S2212_
          
             - [x] TNBC (<5%) with T2-T4 N0 OR T1-T3 N1-N2. 
          
          
             - [x] No Stage IIIC, IIIB T4 N+ OR IBC
        - _FLEX_
          
             - [x] T1 to T3, with smallest size 6mm. Any N
- RAD ONC
  - Adjuvant
    - HR POS
      - NO LINE
        - **MA39**
          
             - [x] Newly Diagnosis of IDC w/ no metastisis 
          Treated with BCS or Mastectomy with no residual disease 
  - Postsurgical
    - NO GROUP
      - NO LINE
        - _PREDICT II_
          
             - [x] Dx of DCIS w/ tumor size <6cm
          
          
             - [x] Eligible for BCS, radiation and/or systemic treatment
- SURG ONC
  - Peri-Surgical
    - NO GROUP
      - NO LINE
        - **CHEST**
          
             - [x] Undergoing Mastectomy + Reconstruction 
        - **Breast ATLAS**
          
             - [x] Undergoing PPX Mastectomy
        - **PRECISION**
          
             - [x] Dx of DCIS and/or IDC undergoing BCS or mastectomy
          
          
             - [x] No hx of prior therapy treatment
        - **SentiNot 2.0**
          
             - [x] Pre-operative diagnosis of DCIS or other suspicious lesion not confirmed to be invasive breast cancer
          
          
             - [x] Willing to forgo initial SLNB and have SLNB as a later second procedure if DCIS is upgraded to invasive cancer
        - **Magellan**
          
             - [x] Non-metastatic patients with node positive breast cancer (cT0-4, N1)
          
          
             - [x] Magseed placement prior to NAC
  - Presurgical
    - NO GROUP
      - NO LINE
        - **ATUSA-iSONO**
          
             - [x] Women with a suspected breast lesion in one of both breasts
          
          
             - [x] Disease T1c or larger 
        - **BCM TISSUE COLLECTION**
          
             - [x] Suspicious lesion receiving an U/S guided biopsy with birads 4b-5
        - **ANGEL**
          
             - [x] Any suspicious lesion receiving a biopsy
- UPCOMING
  - Metastatic
    - HER2
      - 2
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
      - 3
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
      - 4
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
    - HR POS
      - 2
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
      - 3
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
      - 4
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
    - TNBC
      - 2
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
      - 3
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 
      - 4
        - **VISTA**
          
             - [x] HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)
          
          
             - [x] Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines. 